[Multi-target tumor therapy].
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001195:Asbestosis / Q000150:complications / Q000401:mortality / Q000451:nursing*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000401:mortality / Q000451:nursing*; D017326:Clinical Trials, Phase III as Topic; D000077143:Docetaxel; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005971:Glutamates / Q000627:therapeutic use*; D006147:Guanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000451:nursing*; D008654:Mesothelioma / Q000188:drug therapy / Q000401:mortality / Q000451:nursing*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000401:mortality / Q000451:nursing*; D000068437:Pemetrexed; D010997:Pleural Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000451:nursing*; D015996:Survival Rate; D043823:Taxoids / Q000627:therapeutic use; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D004791:Enzyme Inhibitors; D005971:Glutamates; D043823:Taxoids; D000068437:Pemetrexed; D000077143:Docetaxel; D006147:Guanine